Nephrology Dialysis Transplantation

I. Foreword:

Jorge Cannata-Andía, Jutta Passlick-Deetjen, and Eberhard Ritz

Foreword
Nephrol. Dial. Transplant. 15: 1; doi:10.1093/ndt/15.suppl_5.1 [PDF] [Request Permissions]  

II. RECOMMENDATIONS FOR THE MANAGEMENT OF RENAL OSTEODYSTROPHY:

Justin Silver

Molecular mechanisms of secondary hyperparathyroidism
Nephrol. Dial. Transplant. 15: 2-7; doi:10.1093/ndt/15.suppl_5.2 [PDF] [Request Permissions]  

Manuel Anibal Ferreira

Diagnosis of renal osteodystrophy: when and how to use biochemical markers and non-invasive methods; when bone biopsy is needed
Nephrol. Dial. Transplant. 15: 8-14; doi:10.1093/ndt/15.suppl_5.8 [PDF] [Request Permissions]  

Jorge B. Cannata-Andía

Pathogenesis, prevention and management of low-bone turnover
Nephrol. Dial. Transplant. 15: 15-17; doi:10.1093/ndt/15.suppl_5.15 [PDF] [Request Permissions]  

Michael Schömig and Eberhard Ritz

Management of disturbed calcium metabolism in uraemic patients: 1. Use of vitamin D metabolites
Nephrol. Dial. Transplant. 15: 18-24; doi:10.1093/ndt/15.suppl_5.18 [PDF] [Request Permissions]  

Michael Schömig and Eberhard Ritz

Management of disturbed calcium metabolism in uraemic patients: 2. Indications for parathyroidectomy
Nephrol. Dial. Transplant. 15: 25-29; doi:10.1093/ndt/15.suppl_5.25 [PDF] [Request Permissions]  

Michael Schömig and Eberhard Ritz

Management of disturbed calcium metabolism in uraemic patients: 3. Potential perspectives—calcimimetics
Nephrol. Dial. Transplant. 15: 30-31; doi:10.1093/ndt/15.suppl_5.30 [PDF] [Request Permissions]  

Tilman B. Drüeke

Renal osteodystrophy: management of hyperphosphataemia
Nephrol. Dial. Transplant. 15: 32-33; doi:10.1093/ndt/15.suppl_5.32 [PDF] [Request Permissions]  

John Cunningham

Calcium concentration in the dialysate and calcium supplements
Nephrol. Dial. Transplant. 15: 34-35; doi:10.1093/ndt/15.suppl_5.34 [PDF] [Request Permissions]  

José R. Weisinger

Role of hormone replacement in the management of osteoporosis in haemodialysed women: perspectives for the future
Nephrol. Dial. Transplant. 15: 36-37; doi:10.1093/ndt/15.suppl_5.36 [PDF] [Request Permissions]  

III. CLINICAL ALGORITHMS ON RENAL OSTEODYSTROPHY:

Symbols and abbreviations used for the clinical algorithms
Nephrol. Dial. Transplant. 15: 40; doi:10.1093/ndt/15.suppl_5.40 [PDF] [Request Permissions]  

Pathogenesis of renal osteodystrophy, natural history
Nephrol. Dial. Transplant. 15: 41-42; doi:10.1093/ndt/15.suppl_5.41 [PDF] [Request Permissions]  

Management of Calcium-Phosphate metabolism in CRI-patients
Nephrol. Dial. Transplant. 15: 43-44; doi:10.1093/ndt/15.suppl_5.43 [PDF] [Request Permissions]  

Management of calcium-phosphate metabolism in patients on dialysis (1)
Nephrol. Dial. Transplant. 15: 45-46; doi:10.1093/ndt/15.suppl_5.45 [PDF] [Request Permissions]  

Management of calcium-phosphate metabolism in patients on dialysis (2)
Nephrol. Dial. Transplant. 15: 47-48; doi:10.1093/ndt/15.suppl_5.47 [PDF] [Request Permissions]  

Management of hyperphosphataemic patients
Nephrol. Dial. Transplant. 15: 49-50; doi:10.1093/ndt/15.suppl_5.49 [PDF] [Request Permissions]  

Management of hypercalcaemic patients
Nephrol. Dial. Transplant. 15: 51-52; doi:10.1093/ndt/15.suppl_5.51 [PDF] [Request Permissions]  

When to Consider Parathyroidectomy
Nephrol. Dial. Transplant. 15: 53-57; doi:10.1093/ndt/15.suppl_5.53 [PDF] [Request Permissions]  

IV. RECOMMENDATIONS FOR THE MANAGEMENT OF CARDIOVASCULAR RISK FACTORS:

Patrick S. Parfrey

Cardiac disease in dialysis patients: diagnosis, burden of disease, prognosis, risk factors and management
Nephrol. Dial. Transplant. 15: 58-68; doi:10.1093/ndt/15.suppl_5.58 [PDF] [Request Permissions]  

Francesco Locatelli, Daniele Marcelli, Ferruccio Conte, Marco D'Amico, Lucia Del Vecchio, Aurelio Limido, Fabio Malberti, and Donatella Spotti

Cardiovascular disease in chronic renal failure: the challenge continues
Nephrol. Dial. Transplant. 15: 69-80; doi:10.1093/ndt/15.suppl_5.69 [PDF] [Request Permissions]  

Ziad A. Massy

Importance of homocysteine, lipoprotein (a) and non-classical cardiovascular risk factors (fibrinogen and advanced glycation end-products) for atherogenesis in uraemic patients
Nephrol. Dial. Transplant. 15: 81-91; doi:10.1093/ndt/15.suppl_5.81 [PDF] [Request Permissions]  

Christoph Wanner

Importance of hyperlipidaemia and therapy in renal patients
Nephrol. Dial. Transplant. 15: 92-96; doi:10.1093/ndt/15.suppl_5.92 [PDF] [Request Permissions]  

Gérard M. London, Sylvain J. Marchais, Fabien Metivier, and Alain P. Guerin

Cardiovascular risk in end-stage renal disease: vascular aspects
Nephrol. Dial. Transplant. 15: 97-104; doi:10.1093/ndt/15.suppl_5.97 [PDF] [Request Permissions]  

Giuseppe Bianchi

Hypertension in chronic renal failure and end-stage renal disease patients treated with haemodialysis or peritoneal dialysis
Nephrol. Dial. Transplant. 15: 105-110; doi:10.1093/ndt/15.suppl_5.105 [PDF] [Request Permissions]  

Michael Schömig and Eberhard Ritz

Cardiovascular problems in diabetic patients on renal replacement therapy
Nephrol. Dial. Transplant. 15: 111-116; doi:10.1093/ndt/15.suppl_5.111 [PDF] [Request Permissions]  

Ton J. Rabelink, Gerben Truin, and Peter de Jaegere

Treatment of coronary artery disease in patients with renal failure
Nephrol. Dial. Transplant. 15: 117-121; doi:10.1093/ndt/15.suppl_5.117 [PDF] [Request Permissions]  

V. CLINICAL ALGORITHMS ON CARDIOVASCULAR RISK FACTORS IN RENAL PATIENTS:

Symbols and abbreviations used for the clinical algorithms
Nephrol. Dial. Transplant. 15: 125-126; doi:10.1093/ndt/15.suppl_5.125 [PDF] [Request Permissions]  

Assessment of cardiovascular risk factors
Nephrol. Dial. Transplant. 15: 127-128; doi:10.1093/ndt/15.suppl_5.127 [PDF] [Request Permissions]  

Management of dyslipidaemia
Nephrol. Dial. Transplant. 15: 129-130; doi:10.1093/ndt/15.suppl_5.129 [PDF] [Request Permissions]  

General management of hypertension
Nephrol. Dial. Transplant. 15: 131-132; doi:10.1093/ndt/15.suppl_5.131 [PDF] [Request Permissions]  

Antihypertensive management in non-diabetic CRI-patients
Nephrol. Dial. Transplant. 15: 133-134; doi:10.1093/ndt/15.suppl_5.133 [PDF] [Request Permissions]  

Antihypertensive management in PD- and HD-patients
Nephrol. Dial. Transplant. 15: 135-136; doi:10.1093/ndt/15.suppl_5.135 [PDF] [Request Permissions]  

Management of diabetic patients with microalbuminuria
Nephrol. Dial. Transplant. 15: 137-138; doi:10.1093/ndt/15.suppl_5.137 [PDF] [Request Permissions]  

Management of patients with diabetic nephropathy
Nephrol. Dial. Transplant. 15: 139-140; doi:10.1093/ndt/15.suppl_5.139 [PDF] [Request Permissions]  

Management of diabetic patients on dialysis
Nephrol. Dial. Transplant. 15: 141-142; doi:10.1093/ndt/15.suppl_5.141 [PDF] [Request Permissions]  

Management of acute ischaemic heart disease
Nephrol. Dial. Transplant. 15: 143-144; doi:10.1093/ndt/15.suppl_5.143 [PDF] [Request Permissions]  

Management of chronic ischaemic heart disease
Nephrol. Dial. Transplant. 15: 145-146; doi:10.1093/ndt/15.suppl_5.145 [PDF] [Request Permissions]  

Management of heart failure
Nephrol. Dial. Transplant. 15: 147-148; doi:10.1093/ndt/15.suppl_5.147 [PDF] [Request Permissions]  

Microinflammatory state in CRI, PD-/HD-patients
Nephrol. Dial. Transplant. 15: 149-154; doi:10.1093/ndt/15.suppl_5.149 [PDF] [Request Permissions]  

To see an article, click its [Full Text] or [PDF] link. To review many abstracts, check the boxes to the left of the titles you want, and click the 'Get All Checked Abstract(s)' button. To see one abstract at a time, click its [Abstract] link.